Overview

A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease

Status:
Enrolling by invitation
Trial end date:
2027-03-01
Target enrollment:
Participant gender:
Summary
This study is an open-label study to evaluate the safety of long-term administration of inclacumab in participants with sickle cell disease (SCD). Participants in this study will have completed a prior study of inclacumab.
Phase:
Phase 3
Details
Lead Sponsor:
Global Blood Therapeutics